Additional lesions detected in therapeutic scans with 177Lu- DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors

Oncology

Volumn 80, Issue 5-6, 2011, Pages 326-329

  Mirzaei, Siroos ^a   Bastati, Brigitte ^a   Lipp, Rainer W ^b   Knoll, Peter ^a   Zojer, Niklas ^a   Ludwig, Heinz ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

177Lu DOTATATE; 99mTc EDDA HYNIC TOC; 99mTc Tektrotyd; Neuroendocrine tumors; Peptide receptor targeted radionuclide therapy; SPECT CT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE[3 TYROSINE] LUTETIUM 177; DOTATATE; ETHYLENEDIAMINE N,N DIACETIC ACID 6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID OCTREOTIDE[3 TYROSINE] TECHNETIUM 99M; LUTETIUM 177; OCTREOTIDE[3 TYROSINE]; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; TEKTROTYD; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; LIVER TUMOR; LUNG TUMOR; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RECEPTOR AFFINITY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY SCINTISCANNING;

AGED; BONE NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960675336     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000329808     Document Type: Article

References (17)

1. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PPA, O'Carroll A, Patel YC, Schonbrunn A, Taylor JE, Reisine T: Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-88.
2. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW: Localisation of endocrine- related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1:242-244.
3. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427. (Pubitemid 37056239)
4. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, van der Pluijm ME, Visser TJ, Mäcke HR, Krenning EP: Tumour uptake of the radiolabelled somatostatin analogue [DOTA 0 , TYR 3 ]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999; 26: 693-698. (Pubitemid 29338656)
5. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282. (Pubitemid 30167697)
6. Breeman WA, Mearadji A, Capello A, Bernard BF, van Eijck CH, Krenning EP, de Jong M: Anti-tumor effect and increased survival after treatment with [ 177 Lu-DOTA 0 ,Tyr 3 ] octreotate in a rat liver micrometastases model. Int J Cancer 2003; 104: 376-379. (Pubitemid 36249821)
7. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [ 177 Lu-DOTA 0 ,Tyr 3 ] octreotate. Eur J Nucl Med Mol Imaging 2003; 30: 417-422. (Pubitemid 36692868)
8. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP: Combination radionuclide therapy using 177 Lu- and 90 Y-labeled somatostatin analogs. J Nucl Med 2005; 46(suppl 1):13S-17S. (Pubitemid 47619014)
9. Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, Kendler D, Virgolini I: Individualized peptide-relatedradionuclide- therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 2010; 54: 92-99.
10. Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99m Tc-EDDA/HYNIC-TOC: A new 99m Tc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111 In-labelled octreotide derivatives. Eur J Nucl Med 2000; 27: 1318-1325.
11. Parisella MG, Chianelli M, D'Alessandria C, Todino V, Mikolajczak R, Papini E, Dierckx RA, Scopinaro F, Signore A: Clinical indications to the use of 99m Tc-EDDA/HYNICTOC to detect somatostatin receptor-positive neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2010; 54 (Epub ahead of print).
12. Koenig JA, Ewardson JM: Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol 1997; 18: 276-287. (Pubitemid 27353245)
13. Kolan H, Li J, Thakur ML: Sandostatin labeled with 99m Tc: In vitro stability, in vivo validity and comparison with 111 In-DTPA-octreotide. Pept Res 1996; 9: 144-150.
14. Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, Moncayo R: An intrapatient comparison of 99m Tc-EDDA/HYNIC-TOC with 111 In-DTPA- octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003; 44: 708-716. (Pubitemid 39655204)
15. Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M, Mariani G: Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008; 52: 323-333.
16. Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, Kwekkeboom DJ: Comparison of [ 177 Lu-DOTA 0 ,Tyr 3 ] octreotate and [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotide: Which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006; 33: 1346-1351.
17. Glatting G, Landmann M, Wunderlich A, Kull T, Mottaghy FM, Reske SN: Internal radionuclide therapy: Software for treatment planning using tomographic data. Nuklearmedizin 2006; 45: 269-272. (Pubitemid 46031230)